Tracer library / [177Lu]Lu-FAP-2286
Structure of FAP-2286 (unlabelled parent compound, from PubChem)
Unlabelled parent compoundPubChem CID 163408889

[177Lu]Lu-FAP-2286

Also written as [Lu-177]Lu-FAP-2286; FAP-2286; Lu-177-FAP-2286
Radionuclide
Lu-177 t½ 9584.6 min
Modality
Therapy
Production route
—
Stage
Clinical research
Syntheses indexed
1
Bone metastases and bone lesionsBreast cancerGastrointestinal and colorectal cancerGynaecological cancerHepatobiliary and pancreatic cancerDosimetry and biodistribution studiesFAP-directed radioligand therapy

What it is

Compound class
FAP-binding cyclic peptide conjugate (FAP-2286)
Target / mechanism
Targets fibroblast activation protein (FAP) PMID 34168013
Clinical application
Peptide-targeted radionuclide therapy (PTRT) of advanced adenocarcinomas PMID 34168013
Theranostic pair
[68Ga]Ga-FAP-2286

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
Manual synthesis———≥ 93%FAP-228637261473
2023 Eur J Nucl Med Mol Imaging
177Lu-labeling was performed at different conditions, depending on the ligand (Supplementary Table 1).

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

  1. Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results.
    2022 · J Nucl Med · Prospective
  2. Initial Results and Clinical Experiences of [177Lu]Lu-FAP-2286 for Pleural Metastases: A Single-Center Retrospective Study.
    2026 · J Nucl Med · Retrospective
  3. 177 Lu-FAP-2286 Therapy for Advanced Lung Adenocarcinoma With Multiple Metastases : A Promising Last-line Treatment Option.
    2026 · Clin Nucl Med · Clinical study
  4. Visualization of the Gallbladder on 177 Lu-FAP-2286 SPECT/CT Imaging : A Potential Pitfall.
    2026 · Clin Nucl Med · Clinical study

Need this precursor?We can point you to suppliers for [177Lu]Lu-FAP-2286, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 10 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68. Compound class inferred from precursor name (not stated outright) -- PMID 37261473: 'cyclic peptide FAP-2286'. Stage set/updated at stage 23 from PMID 34168013: 'We present the first-in-humans results using 177Lu-FAP-2286 for peptide-targeted radionuclide therapy (PTRT).'. | Stage 30 (2026-09-18): Stage was 'first-in-human'; normalised to 'Clinical research', original wording kept here.
Ask a question